| Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease. | |
| | |
MedLine Citation:
|
PMID: 16299686 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: A variable inhibition of erythropoiesis has been reported in uremic patients with renal anemia receiving anti-renin-angiotensin-system (RAS) drugs (angiotensin-converting-enzyme inhibitors, and angiotensin-receptor-antagonists). The time to development of renal anemia before dialysis is still unknown. METHODS: A retrospective cohort study (1 to 15 years) on records of 327 out-patients (217 males, 110 females) without anemia and with chronic renal insufficiency (creatinine clearance 16 to 75 mL/min) was conducted to estimate the time to development of renal anemia (Hb < 11.5 g/dL in females and Hb < 12.5 g/dL in men), and the time to decrease of Hb by 1 and 2 g/dL or more, irrespective of anemia development. Two treatment groups were analyzed: 142 patients with, and 185 without anti-RAS drugs. RESULTS: Median survival time to development of anemia was 81 months, 59 months to the loss of Hb > 1 g/dL, and 94 months for the loss of Hb > 2 g/dL. Anemia developed significantly earlier in patients with initial Ccr < 40 mL/min and in those with initial Hb < 14 g/dL. In the multivariate analysis (Cox model), male gender, Ccr < 40 mL/min, and Hb < 14 g/dL, in increasing order of relative risk, significantly contributed to prediction of anemia development without any influence of the treatment with anti-RAS drugs. The same results were obtained considering survival to the loss of either Hb > 1 g/dL or Hb > 2 g/dL. CONCLUSIONS: Development of renal anemia in mild to severe chronic kidney disease is not influenced by treatment with anti-RAS drugs. |
| | |
Authors:
|
Antonio Piccoli; Giordano Pastori; Erika Pierobon; Serena Torraca; Michele Andreucci; Massimo Sabbatini; Bruno Cianciaruso |
Related Documents
:
|
16575686 - Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemo... 19002406 - The role of erythropoietin in hemorrhagic shock-induced liver and renal injury in rats. 7485226 - Case report: subacute combined degeneration of the spinal cord from folate deficiency. 1339766 - Application of recombinant human erythropoietin in patients with polycystic kidney dise... 12200746 - Effects of oral creatine supplementation in a patient with melas phenotype and associat... 7581986 - Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow tra... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of nephrology Volume: 18 ISSN: 1121-8428 ISO Abbreviation: J. Nephrol. Publication Date: 2005 Sep-Oct |
Date Detail:
|
Created Date: 2005-11-21 Completed Date: 2006-01-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9012268 Medline TA: J Nephrol Country: Italy |
Other Details:
|
Languages: eng Pagination: 585-91 Citation Subset: IM |
Affiliation:
|
Department of Medical and Surgical Sciences, Nephrology Clinic, University of Padua--Italy. apiccoli@unipd.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anemia
/
chemically induced* Angiotensin-Converting Enzyme Inhibitors / adverse effects* Cohort Studies Erythropoiesis / drug effects Female Humans Kidney Failure, Chronic / complications* Male Middle Aged Receptors, Angiotensin / antagonists & inhibitors* Renin-Angiotensin System / drug effects* Retrospective Studies Survival Analysis |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Receptors, Angiotensin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Interleukin-6 (IL-6) -174 G/C polymorphism in familial Mediterranean fever patients with and without...
Next Document: Risk factors and underlying cardiovascular diseases in incident ESRD patients.